ThursdayJul 02, 2026 10:00 am

Why Wall Street Watches Jefferies’ Earnings Reports Closely

Jefferies Financial may not be as large as Wall Street giants like Goldman Sachs, Morgan Stanley, or JPMorgan Chase, but its earnings reports attract plenty of attention. Many investors and market analysts watch the company's financial results because they often provide an early look at how the investment banking industry is performing. Since Jefferies reports its earnings weeks before the biggest U.S. banks, its results can offer useful clues about what may happen when those larger institutions announce their own quarterly performance. One reason Jefferies is closely followed is that its financial quarter ends earlier than those of many major…

Continue Reading

WednesdayJul 01, 2026 10:40 am

Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial capital to preclinical and early-stage innovation. The Jazz Pharmaceuticals–AbCellera collaboration illustrates how differentiated antibody technologies can command significant financial commitments before entering clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two therapeutic modalities that continue to attract strategic partnerships and acquisitions. Platform technologies and individual drug candidates both represent potential avenues for future partnering, licensing, and collaboration agreements. Recent transactions across the sector demonstrate that pharmaceutical companies are actively seeking access to…

Continue Reading

Contact us: (512) 354-7000